Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

892 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective.
Mody H, Ogasawara K, Zhu X, Miles D, Shastri PN, Gokemeijer J, Liao MZ, Kasichayanula S, Yang TY, Chemuturi N, Gupta S, Jawa V, Upreti VV. Mody H, et al. Among authors: miles d. Clin Pharmacol Ther. 2023 Sep;114(3):530-557. doi: 10.1002/cpt.2986. Epub 2023 Jul 26. Clin Pharmacol Ther. 2023. PMID: 37393588 Review.
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
Deng R, Gibiansky L, Lu T, Flowers CR, Sehn LH, Liu Q, Agarwal P, Liao MZ, Dere R, Lee C, Man G, Hirata J, Li C, Miles D. Deng R, et al. Among authors: miles d. CPT Pharmacometrics Syst Pharmacol. 2024 Apr 15. doi: 10.1002/psp4.13141. Online ahead of print. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38622879 Free article.
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, Ching T, Tandon M, Fink AM, Tausch E, Schneider C, Ritgen M, Böttcher S, Kreuzer KA, Chyla B, Miles D, Wendtner CM, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Al-Sawaf O, et al. Among authors: miles d. J Clin Oncol. 2021 Dec 20;39(36):4049-4060. doi: 10.1200/JCO.21.01181. Epub 2021 Oct 28. J Clin Oncol. 2021. PMID: 34709929 Free PMC article. Clinical Trial.
Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L, Holland J, Miles D, Engel C, Benrimoh N, O'Reilly T, Lacy S. Nguyen L, et al. Among authors: miles d. J Clin Pharmacol. 2015 Sep;55(9):1012-23. doi: 10.1002/jcph.510. Epub 2015 Jun 2. J Clin Pharmacol. 2015. PMID: 25854986 Clinical Trial.
892 results